Acoustic Neuroma Market Report 2026

The acoustic neuroma market size has grown strongly in recent years. It will grow from $1.97 billion in 2025 to $2.13 billion in 2026 at a compound annual growth rate (CAGR) of 8.2%. The growth in the historic period can be attributed to limited awareness of acoustic neuroma, reliance on conventional radiation therapy, slow adoption of advanced imaging modalities, increasing prevalence of hearing disorders, limited surgical treatment centers.

The acoustic neuroma market size is expected to see strong growth in the next few years. It will grow to $2.81 billion in 2030 at a compound annual growth rate (CAGR) of 7.1%. The growth in the forecast period can be attributed to technological advancements in mri and ct-scan, growth of proton therapy and stereotactic radiosurgery, rising investments in hospitals and surgical centers, increasing patient awareness and early diagnosis, expansion of specialized treatment centers. Major trends in the forecast period include increasing adoption of advanced imaging techniques, rising preference for minimally invasive treatments, growth in proton therapy and stereotactic radiosurgery, expansion of personalized treatment approaches, increasing awareness about vestibular schwannoma symptoms.

The rising investment in the healthcare sector is expected to drive the growth of the acoustic neuroma market in the coming years. The healthcare sector encompasses a broad range of services and facilities aimed at promoting health, providing medical care, and improving overall well-being for individuals and populations. Investments in the healthcare sector are fueled by increasing demand, technological advancements, regulatory developments, and global health challenges. Such investments support innovation in diagnostics and treatments for acoustic neuroma, enhancing patient outcomes and quality of life. For instance, in April 2025, data from the Office for National Statistics, a UK-based independent producer of official statistics, indicated that UK healthcare spending reached approximately £317 billion in 2024, reflecting a 6.5% nominal increase compared with 2023. Therefore, the rising investment in the healthcare sector is contributing to the growth of the acoustic neuroma market.

Major companies operating in the acoustic neuroma market are focusing on developing advanced solutions, such as high-precision image-guided delivery, to improve treatment accuracy, minimize damage to surrounding tissues, and enhance patient outcomes. High-precision image-guided delivery is a technological feature in radiosurgery that enables real-time targeting and tracking of tumors, ensuring precise radiation delivery to affected areas. For instance, in April 2025, Accuray Incorporated, a US-based medical device company specializing in advanced radiosurgery systems, released new clinical data on the CyberKnife System, highlighting its capabilities in delivering SRS and SBRT. Designed to treat central nervous system (CNS) tumors, including acoustic neuroma, the system offers noninvasive, targeted treatment options that enhance safety and clinical effectiveness.

In April 2024, Elekta AB, a Sweden-based medical technology company providing treatment solutions for acoustic neuroma, partnered with MIM Software Inc. to integrate Elekta’s radiation therapy platforms with MIM’s vendor-agnostic auto-contouring and treatment-planning software. Through this collaboration, Elekta aims to accelerate innovation in radiation oncology, streamline clinical workflows, improve treatment precision, and enhance patient experience by reducing planning time and optimizing radiotherapy delivery for conditions such as acoustic neuroma. MIM Software Inc. is a US-based provider of medical imaging and AI-driven treatment-planning solutions.

Major companies operating in the acoustic neuroma market are Pfizer Inc, F. Hoffmann-La Roche AG, Merck & Co. Inc., Sanofi S.A., AstraZeneca plc, Novartis AG, GSK plc, Amgen Inc., Teva Pharmaceuticals Industries Ltd, General Electric Company, Siemens Healthineers, Canon Medical Systems Corporation, Toshiba Medical Systems Corporation, Shimadzu Corporation, Varian Medical Systems, Elekta AB, Medtronic plc, Olympus Corporation, Cochlear Limited, Brainlab AG, Natus Medical Incorporated, Abbott Laboratories.

North America was the largest region in the acoustic neuroma market in 2025. The regions covered in the acoustic neuroma market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the acoustic neuroma market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the acoustic neuroma market by increasing the cost of imported imaging equipment such as MRI and CT scanners, as well as radiation therapy and proton therapy devices. Segments like stereotactic radiosurgery and proton therapy are most affected, particularly in regions such as North America, Europe, and Asia-Pacific where high-end medical equipment is often imported. While tariffs raise operational costs and treatment expenses, they have encouraged local manufacturing of diagnostic and therapeutic equipment, fostering regional innovation and self-reliance.

The acoustic neuroma market research report is one of a series of new reports that provides acoustic neuroma market statistics, including acoustic neuroma industry global market size, regional shares, competitors with a acoustic neuroma market share, detailed acoustic neuroma market segments, market trends and opportunities, and any further data you may need to thrive in the acoustic neuroma industry. This acoustic neuroma market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Acoustic neuroma, also known as vestibular schwannoma, is a non-cancerous tumor that forms on the vestibular nerve, which connects the inner ear to the brain and is responsible for transmitting balance and hearing information. Acoustic neuromas typically grow slowly and do not spread to other parts of the body. Common symptoms include hearing loss, tinnitus (ringing in the ear), dizziness, imbalance, facial numbness or weakness, and coordination problems.

The main types of acoustic neuroma are unilateral vestibular schwannomas and bilateral vestibular schwannomas. Unilateral vestibular schwannomas occur on one side of the vestibulocochlear nerve, affecting both hearing and balance functions. Treatments include medications, anticonvulsants, radiation therapy, proton therapy, and stereotactic radiosurgery, while diagnosis is performed using magnetic resonance imaging (MRI), computed tomography (CT) scans, and hearing tests. The end users of these treatments include hospitals, clinics, and surgical centers.

The acoustic neuroma market consists of revenues earned by entities by providing services such as neurosurgery, hearing tests, auditory rehabilitation, and counseling and support services for patients and families. The market value includes the value of related goods sold by the service provider or included within the service offering. The acoustic neuroma market also includes sales of hearing aids, surgical instruments, balance therapy equipment, and assistive listening devices. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.